T r e at m e n t f o r mental illness and substance use disorders are important components of overall health care. However, 89 percent of the twenty-four million people age twelve and older with a substance use or dependence disorder in 2006 received no specialty treatment for their condition. 1 Of the thirty-three million adults age eighteen and older needing mental health (MH) treatment, 31 percent received inadequate care or none at all. 2 At the same time, the United States is experiencing the largest increase in adolescent suicide rates in fifteen years-one indication of the severe consequences of unmet treatment needs. 3 Presented here for the first time are forecasts through 2014 of spending on behavioral health care, prepared in the context of the historical spending estimates for mental health and substance abuse (MHSA) treatment for the Substance Abuse and Mental Health Services Administration (SAMHSA). 4 Although our forecasts cannot specifically address the reasons for unmet MHSA treatment needs, they can uncover broad trends in spending that provide clues to these deeper issues. Baseline views of future MHSA spending provide a framework for understanding what might influence spending over the next decade: how much the nation is likely to spend on MHSA treatment, how much spending is predicted to be directed to each provider type, who is expected to pay for care, and how spending is forecasted to change over time. Our forecasts are intended to present decisionmakers with a realistic picture of probable future MHSA spending if historical trends as well as advances in treatment and technology (including prescription drugs) continue as they have in the past.
Despite continuing MHSA treatment shortfalls, one in five nonelderly adults received treatment for emotional disorders during 2001-2003, a sizable increase over treatment rates a decade earlier. 5 Effective planning to continue MHSA treatment expansion depends on rational and cost-effective resource coordination. Our objective is to provide one tool that can help policymakers envision future funding requirements and the potential implications of policy inaction.
Projection Methods
These projections of MH and SA spending were forecasted from historical estimates produced as part of the SAMHSA spending estimates. These forecasts are modeled after the general format of the National Health Expenditure Accounts (NHEA) produced by the Centers for Medicare and Medicaid Services (CMS). 6 In both the historical estimates and the projections, MHSA treatment spending was identified by a first-listed MH or SA diagnosis. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes defined these conditions: "mental disorders" (291, 292, 295-304, 305.2-305.9, and 306-314) and MH and SA complications related to pregnancy (648.3 and 648.4). We excluded dementias (290), transient and persistent mental disorders due to conditions classified elsewhere (293 and 294), tobacco abuse disorders (305.1), specific delays in development (315), mental retardation (317-319), cerebral degenerations (331.0), and psychic factors associated with disease classified elsewhere (316).
Historical estimates for key years are presented; the methods used to produce them have been described in an earlier report. 7 To project MHSA spending, we predominantly used a five-factor growth model, a technique used in the past by the CMS in producing projections of all health spending. This model allocated historical spending growth to changes in population, use per person, general inflation, service-specific net price increases, and a residual (intensity of service use). Projections of growth in population and general inflation were taken from the Old-Age, Survivors, and Disability Insurance (OASDI) Trustees Report; projections of increases in all other factors were developed as extensions of historical trends, modified by other near-term (2004) (2005) inflation, economic, and employment indicators when available. 8 These forecasts reflect laws in place at the time they were prepared, including Medicare prescription drug coverage. Other factors, however, that are likely to occur and may influence future spending trends are not included in these forecasts, because their effects are currently unknown. In particular, the imminent and serious mental health needs of returning combat veterans, changes in the U.S. political landscape, economic downturns, shifts in Medicaid policies, and natural disasters can alter spending trends. More speculative factors, such as enactment of the longdebated federal MHSA benefit parity, once again under consideration by Congress, could H e a l t h T r a c k i n g drugs account for a higher proportion of spending in MH than in all health, and their use is anticipated to grow rapidly over the next decade, adding more to the overall growth rate of MH spending than to all-health spending. Despite falling as a share of all-health spending, MHSA spending is rising as a share of the economy-from 0.95 percent of U.S. gross domestic product (GDP) in 1986 to an expected 1.24 percent in 2014. Spending on MH alone is forecasted to outpace economic growth, but SA spending growth is not; as a result, SA spending is likely to fall slightly as a share of GDP by 2014 (Exhibit 2).
n Mental health spending. Over the projection period, private health insurance spending is expected to increase as a share of MH spending (from 24 percent to 26 percent), while out-ofpocket spending shares are anticipated to fall (from 14 percent to 12 percent) (Exhibit 3). These changes reflect a predicted shift in MH prescription drug spending for the Medicare elderly and disabled population in 2006 from out of pocket to Medicare; to a more limited degree, Medicare drug coverage also dampens some of the growth in private insurance spending for drugs. After this one-time adjustment, private insurance shares are expected to rise slightly, driven primarily by subsequent increases in private insurance drug spending for the nonMedicare population.
MH provider spending. Spending on prescription drugs drives MH spending and is expected to be responsible for 37 percent of the increase in overall MH spending between 2003 and 2014. 10 The meteoric rise in the use of prescription MH medications over the past decade has had many positive effects on the treatment of mental illnesses. Drug therapies with increased efficacy, fewer safety issues, and improved side-effect profiles have emerged since the early 1990s and have led to greatly expanded use, especially when prescribed by primary care physicians, who have become more comfortable with some types of MH medications. 11 The easier access and reduced stigma of receiving MH medications from primary care physicians rather than psychiatrists has contributed to use and spending increases.
The slowdown in drug spending growth since 1999 has tempered expectations for rapid all-health prescription drug spending growth in the future. 12 The switch to generic medications; the use of tiered formularies that require higher copayments for newer, more expensive drugs; step therapy (prescribing older, less costly medications before newer, more costly drugs will be covered); the slump in new drug development that is expected to abate only later in the projection period; increased availability of generic alternatives; and a rise in black-box warnings about drug side effects together have dampened spending growth expectations on prescription MH drugs over the next decade. 13 However, spending on prescription drugs is still expected to outpace all other MH and allhealth spending growth through the coming decade. 14 We forecast growth in prescription MH drug spending (averaging 9.2 percent for 2003-2014) that will be more than one-third faster than growth in MH spending for all treatment and this will raise the drug share of MH spending to 30 percent by 2014 from 23 percent in 2003 (Exhibit 3). Nevertheless, MH drug spending increases are projected to be more modest than the historical rate, which averaged 14. psychotropic medications are often written by these nonspecialty physicians without specifically listing an accompanying principal MH diagnosis used to identify MH spending.
Based on historical trends, we project slightly slower growth for general hospitals (averaging 6.2 percent annually) and continued slow growth in spending for specialty psychiatric hospitals (averaging 2.1 percent annually) during the projection period (Exhibit 3). Low rates of MH hospital admissions and shorter lengths-of-stay are hallmarks of behavioral health plans' utilization management, which has helped to reduce costs of MH health treatment by closely monitoring inpatient services. Utilization management dominated service delivery during the mid-1990s and was particularly evident in freestanding psychiatric hospitals. Although these trends are expected to continue through the next decade, decline in shares of spending for specialty hospitals will be more moderate (from 12 percent in 2003 to 7 percent in 2014) than they were historically (from 25 percent in 1986 to 12 percent in 2003). The ultimate effect on hospitals of the Medicare inpatient prospective payment system (PPS) for psychiatric stays after the 2005-2007 transition period is currently unknown, but it holds the potential to alter incentives for providers of psychiatric inpatient care as the new payment rates are implemented. 15 In addition to hospitals, growth in spending for MSMHOs that deliver a wide range of outpatient and residential MH services is also forecasted to increase more slowly than all MH spending over the coming decade. This slow projected growth (4.4 percent average annual increase) is slightly faster than the trends in recent historical spending (3.2 percent between 1994 and 2003; data not shown).
n Substance abuse spending. Spending on SA treatment is expected to total $35 billion in 2014-an anticipated 15 percent of MHSA spending. However, this forecast may underestimate actual spending on SA treatment. MH and SA conditions often occur in combination, but spending in this report is classified only by the principal diagnosis. 16 Providers typically classify a mental health condition as principal when it co-occurs with SA because MH benefits are often more generous and likely to be paid by an insurer. 17 Growth in SA spending is forecasted to average 5.0 percent between 2003 and 2014, slightly faster than the rate of 4.8 percent in the 1986-2003 historical period (Exhibit 4). Over the next decade, SA spending growth is expected to continue to increase at slower rates than MH health spending, mainly because pharmacotherapy, which has driven increases in MH spending, currently plays only a small role in SA treatment. This is expected to result in an SA share that falls from 1.3 to 1.0 percent of all-health spending (Exhibit 1). Moreover, growth in SA spending increases at a slower pace than growth in the economy, with the SA share of GDP falling slightly between 2003 and 2014 (Exhibit 2).
SA payer spending. Public SA spending, which accounted for more than three-quarters of all SA spending in 2003, is anticipated to swell to 83 percent by 2014, as public programs assume increasing responsibility for treatment (Exhibit 4). While private financing of SA treatment is forecasted to increase at faster-thanhistorical rates (2.5 percent annually), growth is expected to still remain at less than half the rate of public SA spending increases.
Each category of public SA spending other than other federal (whose share is expected to remain stable) is likely to increase its spending share over the projection period. SA spending by other state and local governments is projected to reach 45 percent of all SA spending by 2014, making this source the dominant payer for SA services. This is a much larger share of SA spending than the 6 percent that is anticipated for all-health spending in 2014, indicating the disproportionate reliance of this industry on state and local government funding. Medicaid is the second-largest payer for SA treatment, accounting for a projected 20 percent of SA treatment spending in 2014. By 2014, Medicaid and other state and local programs together are forecasted to finance 65 percent of SA treatment.
Historically, a dominating characteristic of private SA spending has been the lack of funding increases from private health insurance, which declined an average of 1.6 percent annually between 1986 and 2003 (Exhibit 4). We expect private insurance SA spending growth to accelerate somewhat during the projection period-to 1.3 percent annually. However, actual spending in 2014 is anticipated to be below that estimated for 1986, and the private health insurance share of SA spending is expected to continue falling (from 10 percent in 2003 to 7 percent in 2014). Barriers to SA in-H e a l t h T r a c k i n g 
2003-2014
Total SA spending (billions) $9. surance coverage exist that are not present in medical/surgical coverage, including annual and lifetime limits for inpatient hospital stays and outpatient visits, and higher cost sharing through deductibles and coinsurance. 18 In addition, the increasing emphasis on drug-free workplaces in industries such as transportation has heightened employees' reluctance to file claims for SA treatment through job-based insurance. Out-of-pocket spending is also expected to accelerate, but growth is projected to remain slower than for all SA spending. SA provider spending. Specialty SA centers (SSACs) have emerged as major providers in the delivery of SA treatment, with spending for their services increasing from 19 percent of SA spending in 1986 to a projected 42 percent in 2014 (Exhibit 4). SSACs are multidimensional facilities that deliver services ranging from outpatient care to residential services. In contrast to MH spending, prescription drugs have an insignificant impact on SA treatment spending and account for less than 1 percent of SA spending throughout the 1986-2014 period, despite the addition of several new medications (acamprosate, naltrexone IM, buprenorphine) as treatment options.
Conclusion
These projections suggest several important issues for policymakers to track over the coming decade. First, prescription drug spending is expected to increase its share of MH spending. Although treatment with medications is more cost-effective, widely accessible, and associated with less stigma than other treatment mechanisms, there are many unanswered questions about the efficacy of certain medications for children, and interactions and side effects for adults, especially the elderly. Some question the ability of nonpsychiatric physicians, who prescribe an increasing share of MH medications, to properly diagnose some of the more complicated MH conditions and follow up with patients to ensure high-quality treatment. More research is needed to address these issues.
Second, both MH and SA spending relies more on public payers than does all health spending. The effects of payer changes, such as the implementation of the Medicare inpatient PPS for psychiatric hospital stays and Medicare coverage of prescription drugs, likely will be compounded for the MHSA providers (especially those specializing in MHSA treatment alone), magnifying potentially unintended consequences that often surround new policies. The effects on access and spending should be carefully monitored.
Third, the continued decline in private insurance spending for SA treatment, attributable at least in part to greater limits on benefits and utilization controls, is expected to cause spending from this source in 2014 to be lower than it was in 1986. Treatment costs are borne instead mostly by state and local governments, which struggle to maintain funding for these critical services. Private insurance coverage needs renewed policy consideration, given the tremendous costs for individuals and society as substance use disorders go untreated.
The projections of MHSA spending will help to sharply focus policymakers on critical issues that are likely to emerge over the next decade; they are a tool to help understand the future implications of current trends. By envisioning the future, analysts and lawmakers can help redesign it by taking action today. The unmet need for MHSA treatment, which can result in or exacerbate a variety of physical health problems, is great, and the consequences too large to ignore.
